By appointment only
Monday to Friday 8:00 a.m. to 4:00 p.m.
Doctor's referral required
Appointment cancellation: 24 hours in advance
For patients living remotely, consultation request may be evaluated through electronic means, and if necessary, appointment may be booked subsequently (radiation oncology only).
Where to find us
Pavillion F – Segal Cancer Centre, 7th floor, E-728
Pavillion G – Room G-304
Main entrance at 3755 Côte-Sainte-Catherine Road
Turn LEFT and walk to the end of hallway to the top of the stairs
Turn LEFT again and take the Pavilion G elevators up to the 3rd floor
Turn LEFT and walk to reception counter
Pavilion G- Room G002
Main entrance at 3755 Côte-Sainte-Catherine Road
Turn LEFT and walk to the end of hallway to the top of the stairs, go down to the food court, turn to the left; go to the elevator and the office is on your right and walk to the reception counter.
Or Turn LEFT again and take the Pavilion G elevators up to the ground floor and turn LEFT when you exit the elevator and walk to reception counter
Deciding where to be treated is a crucial step of the cancer treatment. The JGH is recognized as one of the leaders in pioneering new ways to screen and treat colorectal cancer, so we can provide our patients with an optimal treatment plan specifically designed for each patient. Our cancer genetics team, working with gastroenterology and colorectal surgery, detects and follows large family cohorts with hereditary cancer risks. Each year we care for more than 200 newly diagnosed patients with colon and rectal cancer. We treat patients from the earliest stages to more advanced and complex stages and forms of the disease.
We believe that a broad team of experts is essential in providing compassionate cancer care. Therefore, our staff includes variety of colorectal cancer specialists from diverse fields, including surgery, medical oncology, radiation therapy, radiology, pathology, cancer genetics, cancer rehabilitation, psychosocial service. Many of them nationally or internationally recognized.
Treatment decisions are taken in frequent tumour board meetings to discuss specific cases and decide best treatment options to each cancer patient. Clinical trials are an integral aspect of care, providing patients with access to novel therapeutics and new treatment approaches.
To assure the best quality patient care by advancing in science, prevention and management of disorders of the colon, rectum and anus as well as improving the recognition, treatment and ultimate eradication of these diseases. To provide medical students, resident, fellows and practicing surgeons with up to date knowledge of these diseases. To provide our patients a centre of excellence where patients with colorectal disease are cared for compassionately and fellows and residents are taught modern surgical techniques.
Our research includes topics in medical oncology, surgery and radiation therapy. Our medical oncologists are responsible for systemic therapy, including chemotherapy, as well as more advanced and novel therapeutics: so-called targeted agents and immunotherapies. The medical oncology team has helped develop many of these, and has significant experience with these treatments. Many of these treatments are selected based on the expression of specific 'biomarkers', such as proteins or gene mutations. The molecular diagnostics team at the JGH routinely performs test to detect these biomarkers for all of our patients.
Clinical research provides new treatment opportunities to our patients, including access to new drugs and biological agents, including immune activating and targeted treatments. The Clinical Research Unit and Clinical Research Program, provide a range of dynamic clinical trials available to patients across the range of stages and tumor sub-types.
In addition to the surgery research program, our GI research and development program attract local and international researchers, trainees and visitors. We are a world leader in the field of high dose rate endorectal brachytherapy for patients with rectal cancer, and in North America on electronic brachytherapy with 50 Kv X-Ray for rectal cancer. We have multiple innovative studies testing new-targeted radiation treatment as well as quality of life studies, function evaluation and patient’s treatment preferences. The team is composed of dynamic and academic radiation oncologists, medical physicists with a large postgraduate Master and PhD student program in the field of inverse planning brachytherapy, new radionuclides, electronic and high dose rate brachytherapy, artificial intelligence and image-guided brachytherapy.
Carol-Ann Vasilevsky, MD. – Chief of Division
Phone:(514) 340-8222 x 24636
Phone: (514) 340-8288
Fax: (514) 340-7548
New Referrals: Virginia McLaughlin
Phone: (514) 340-8222 x 26020
Secretary: Joussy Mikhail
Phone: (514) 340-8222 x 23460
Fax (514) 340-8302
Nurse Pivot CRC: Natalie Leon
Nurse Pivot AYAO: Daphnee Lemoussenery